Amgen Inc. $AMGN Shares Acquired by Dimensional Fund Advisors LP

Key Points

• Dimensional Fund Advisors LP increased its Amgen stake by 2.3% in the first quarter, bringing its holdings to 3.3 million shares valued at about $1.16 billion. Institutional investors and hedge funds still own a large majority of the company, at 76.5% of shares.
• Amgen delivered a stronger-than-expected quarter, reporting EPS of $5.15 versus estimates of $4.77 and revenue of $8.62 billion, slightly above forecasts. The company also raised its FY2026 guidance to 21.7–23.1 EPS.
• Sentiment is mixed around Amgen’s pipeline and stock outlook: the company has seen positive obesity-pipeline progress, but it also halted key bemarituzumab and rocatinlimab trials. Analyst views remain cautious overall, with a consensus Hold rating and average price target of $356.62.

Dimensional Fund Advisors LP lifted its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 2.3% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 3,304,344 shares of the medical research company's stock after buying an additional 73,365 shares during the period. Dimensional Fund Advisors LP owned 0.61% of Amgen worth $1,162,649,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Anfield Capital Management LLC raised its holdings in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock valued at $25,000 after acquiring an additional 70 shares during the last quarter. Dogwood Wealth Management LLC boosted its holdings in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock worth $25,000 after purchasing an additional 55 shares during the last quarter. Tower View Wealth Management LLC boosted its holdings in shares of Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company's stock worth $29,000 after purchasing an additional 63 shares during the last quarter. Manning & Napier Advisors LLC grew its position in shares of Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock valued at $32,000 after purchasing an additional 32 shares during the period. Finally, Olistico Wealth LLC purchased a new stake in shares of Amgen in the fourth quarter valued at $33,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Stock Performance

Shares of AMGN opened at $366.29 on Monday. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $391.29. The firm has a market capitalization of $197.69 billion, a P/E ratio of 25.49, a price-to-earnings-growth ratio of 3.71 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The stock's fifty day simple moving average is $347.69 and its 200 day simple moving average is $350.53.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm's quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities research analysts forecast that Amgen Inc. will post 22.31 earnings per share for the current year.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company's stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.85% of the company's stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen advanced its obesity pipeline with fresh Phase 1 data on AMG 133 injection formats, which could support long-term growth if the program continues to show promise. Amgen Advances Obesity Pipeline With Fresh Data on AMG 133 Injection Formats
• Positive Sentiment: Amgen’s stock was highlighted in market coverage as teasing a buy point, suggesting technical traders may see room for upside if broader market conditions stabilize. Stock Market Today: Dow Sees Red While Amgen Shares Tease A Buy Point (Live Coverage)
• Neutral Sentiment: Amgen remains a candidate for another earnings beat, according to recent coverage pointing to its history of topping estimates and solid fundamentals. Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate for Amgen to $23.58 from $23.62 and kept a Hold rating, a modest negative for sentiment but not a major change in the outlook. Amgen Inc. NASDAQ: AMGN Free Report
• Negative Sentiment: Amgen halted a late-stage bemarituzumab gastric cancer trial, adding uncertainty to part of its oncology pipeline and pressuring investor expectations. Amgen Halts Bemarituzumab Gastric Cancer Trial, Shifting Oncology Expectations
• Negative Sentiment: Amgen also terminated a key Phase 3 rocatinlimab eczema study, another setback that may raise concerns about the durability of its pipeline growth. Amgen’s Rocatinlimab Eczema Trial Termination Jolts Investor Expectations

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Freedom Capital upgraded Amgen from a "hold" rating to a "strong-buy" rating in a research note on Thursday, May 7th. Wall Street Zen cut Amgen from a "buy" rating to a "hold" rating in a report on Saturday, June 27th. Morgan Stanley lowered their price target on Amgen from $340.00 to $333.00 and set an "equal weight" rating for the company in a report on Wednesday, July 8th. Weiss Ratings downgraded shares of Amgen from a "buy (b)" rating to a "buy (b-)" rating in a research note on Wednesday. Finally, Canaccord Genuity Group assumed coverage on shares of Amgen in a report on Monday, April 20th. They set a "hold" rating and a $366.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $356.62.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.